These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38146985)

  • 21. Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022.
    Mefsin YM; Chen D; Bond HS; Lin Y; Cheung JK; Wong JY; Ali ST; Lau EHY; Wu P; Leung GM; Cowling BJ
    Emerg Infect Dis; 2022 Sep; 28(9):1856-1858. PubMed ID: 35914518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.
    Baz M; Deshpande N; Mackenzie-Kludas C; Mordant F; Anderson D; Subbarao K
    Emerg Infect Dis; 2022 Nov; 28(11):2352-2355. PubMed ID: 36191630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two Cases of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections Caused by the Omicron Variant (B.1.1.529 Lineage) in International Travelers to Japan.
    Maruki T; Iwamoto N; Kanda K; Okumura N; Yamada G; Ishikane M; Ujiie M; Saito M; Fujimoto T; Kageyama T; Saito T; Saito S; Suzuki T; Ohmagari N
    Clin Infect Dis; 2022 Aug; 75(1):e354-e356. PubMed ID: 34979547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Omicron BA.5 Infections in Vaccinated Persons, Rural Uganda.
    Mugisha J; Mpairwe B; Newton R; Cotten M; Phan MVT
    Emerg Infect Dis; 2023 Jan; 29(1):224-226. PubMed ID: 36529453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of incubation periods of infections of Omicron variants BA.2 and BF.7 in Beijing].
    Xu X; Cai YX; Liu YH; Shen Y; Pan Y; Yao H; Wang XL; Yang P
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Sep; 44(9):1397-1401. PubMed ID: 37743272
    [No Abstract]   [Full Text] [Related]  

  • 26. Shorter Incubation Period among Unvaccinated Delta Variant Coronavirus Disease 2019 Patients in Japan.
    Ogata T; Tanaka H; Irie F; Hirayama A; Takahashi Y
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends of Mismatches in Real-Time RT-PCR Assays Developed by the National Institute of Infectious Diseases, Japan for Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2.
    Shirato K; Ujike M; Kawase M
    Jpn J Infect Dis; 2023 May; 76(3):204-206. PubMed ID: 36575025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022.
    Sofonea MT; Roquebert B; Foulongne V; Morquin D; Verdurme L; Trombert-Paolantoni S; Roussel M; Bonetti JC; Zerah J; Haim-Boukobza S; Alizon S
    Emerg Infect Dis; 2022 Jul; 28(7):1355-1365. PubMed ID: 35642476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan.
    Li Y; Yamamoto S; Oshiro Y; Inamura N; Nemoto T; Horii K; Takeuchi JS; Mizoue T; Konishi M; Ozeki M; Sugiyama H; Sugiura W; Ohmagari N
    J Hosp Infect; 2023 Apr; 134():97-107. PubMed ID: 36805085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The First Case of a Child Infected with SARS-CoV-2 Omicron Variant in Japan, December 2021.
    Horigome A; Yamanaka J; Takasago S; Iwamoto N; Saito T; Shichino H
    Jpn J Infect Dis; 2023 Jan; 76(1):69-71. PubMed ID: 36047182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased Stability of SARS-CoV-2 Omicron Variant over Ancestral Strain.
    Chin AWH; Lai AMY; Peiris M; Man Poon LL
    Emerg Infect Dis; 2022 Aug; 28(7):1515-1517. PubMed ID: 35550234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
    Yamayoshi S; Iwatsuki-Horimoto K; Okuda M; Ujie M; Yasuhara A; Murakami J; Duong C; Hamabata T; Ito M; Chiba S; Kobayashi R; Takahashi S; Mitamura K; Hagihara M; Shibata A; Uwamino Y; Hasegawa N; Ebina T; Izumi A; Kato H; Nakajima H; Sugaya N; Seki Y; Iqbal A; Kamimaki I; Yamazaki M; Kawaoka Y; Furuse Y
    Emerg Infect Dis; 2022 Nov; 28(11):2198-2205. PubMed ID: 36198306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USA.
    Seid AG; Yirko T; Sayeed S; Plipat N
    Emerg Infect Dis; 2022 Sep; 28(9):1911-1913. PubMed ID: 35914519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant BA.1/BA.2 SARS-CoV-2 Virus in Arriving Travelers, Hong Kong, February 2022.
    Gu H; Ng DYM; Liu GYZ; Cheng SSM; Krishnan P; Chang LDJ; Cheuk SSY; Hui MMY; Lam TTY; Peiris M; Poon LLM
    Emerg Infect Dis; 2022 Jun; 28(6):1276-1278. PubMed ID: 35394420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Omicron Replacement of Delta as Predominant Variant, Puerto Rico.
    Santiago GA; Volkman HR; Flores B; González GL; Charriez KN; Huertas LC; Van Belleghem SM; Rivera-Amill V; Major C; Colon C; Tosado R; Adams LE; Marzán M; Hernández L; Cardona I; O'Neill E; Paz-Bailey G; Papa R; Muñoz-Jordan JL
    Emerg Infect Dis; 2023 Apr; 29(4):855-857. PubMed ID: 36878014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Ito T; Ikeda H; Kamura H; Motohashi I; Kimura Y; Komino M; Arai H; Kuwamitsu O; Akuzawa N; Sando E; Morikawa T; Imura H; Inoue H; Hayakawa T; Teshigahara O; Ohara Y; Suzuki M; Morimoto K
    Expert Rev Vaccines; 2023; 22(1):288-298. PubMed ID: 36883371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early SARS-CoV-2 Reinfections within 60 Days and Implications for Retesting Policies.
    Nevejan L; Cuypers L; Laenen L; Van Loo L; Vermeulen F; Wollants E; Van Hecke I; Desmet S; Lagrou K; Maes P; André E
    Emerg Infect Dis; 2022 Aug; 28(8):1729-1731. PubMed ID: 35738346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021.
    Vauhkonen H; Nguyen PT; Kant R; Plyusnin I; Erdin M; Kurkela S; Liimatainen H; Ikonen N; Blomqvist S; Liitsola K; Lindh E; Helve O; Jarva H; Loginov R; Palva A; Hannunen T; Hannula S; Parry M; Kauppi P; Vaheri A; Sironen T; Lappalainen M; Savolainen-Kopra C; Smura T; Vapalahti O
    Emerg Infect Dis; 2022 Jun; 28(6):1229-1232. PubMed ID: 35378057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.
    Kislaya I; Casaca P; Borges V; Sousa C; Ferreira BI; Fonte A; Fernandes E; Dias CM; Duarte S; Almeida JP; Grenho I; Coelho L; Ferreira R; Ferreira PP; Borges CM; Isidro J; Pinto M; Menezes L; Sobral D; Nunes A; Santos D; Gonçalves AM; Vieira L; Gomes JP; Leite PP; Nunes B; Machado A; Peralta-Santos A
    Emerg Infect Dis; 2023 Mar; 29(3):569-575. PubMed ID: 36737101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.